Academic Article RDF
pages:- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- more...
- A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity
- A peptoid antagonist of VEGF receptor 2 recognizes a 'hotspot' in the extracellular domain distinct from the hormone-binding site
- A PERIOD inhibitor buffer introduces a delay mechanism for CLK/CYC-activated transcription
- A peripheral and central t-cell antigen recognized by a monoclonal thymocytotoxic autoantibody from new-zealand black mice
- A periplasmic reducing system protects single cysteine residues from oxidation
- A permutation test for stabilization of polypeptide helices by sequence-dependent side chain interactions: Characterization of a helix initiation site within the myohemerythrin sequence 76-87
- A permutational approach toward protein-DNA recognition
- A persistent RNA-DNA hybrid is formed during transcription at a phylogenetically conserved mitochondrial DNA sequence
- A perspective on mechanisms of protein tetramer formation
- A perspective on the structural and functional constraints for immune evasion: insights from influenza virus
- A PET imaging strategy for interrogating target engagement and oncogene status in pancreatic cancer
- A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
- A ph sensitive colorometric assay for the high-throughput screening of enzyme inhibitors and substrates: A case study using kinases
- A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries
- A phage display system with unnatural amino acids
- A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone
- A pharmacological network for lifespan extension in Caenorhabditis elegans
- A pharmacophore modeling approach to design new taxol (R) mimics: towards the synthesis of potential anticancer and MDR-reversing agent
- A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
- A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
- A phase i clinical trial of the hu14.18-il2 (emd 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the children's oncology group
- A phase i/ib trial of murine monoclonal anti-gd2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma - a report of the children's cancer group
- A phase-i study of human mouse chimeric antiganglioside gd2 antibody ch14.18 in patients with neuroblastoma
- A phase-i study of neuroblastoma with the antiganglioside gd2 antibody 14.G2a
- A phenotype survey of 36 mutant mouse strains with gene-targeted defects in glycosyltransferases or glycan-binding proteins
- A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia
- A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor
- A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate
- A phosphoarginine containing peptide as an artificial SH2 ligand
- A phosphopantetheinylating polyketide synthase producing a linear polyene to initiate enediyne antitumor antibiotic biosynthesis